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The massive strides made in human genetics in the last 10 years 
would not have been possible without the diligent and insightful 
work of the pioneers in human genetics. This is particularly true 
in South Africa (SA), where a small community of scientists and 
clinicians have been responsible for the application of scientific/
medical advances into the wider SA population. Prof. Peter Beighton 
spearheaded the initial retinal degenerative disorder (RDD) research 
project in 1985, the emphasis being the identification of genes 
underlying RDD in SA families. 
The RDD genes affect the rod and cone photoreceptors of the 
retina, resulting in retinal degeneration and consequent loss of vision, 
which may result in total blindness. At the time the project was 
initiated, it was believed there were, at most, three genes responsible 
for the most common RDD, namely retinitis pigmentosa (RP): one 
each for the autosomal dominant (ADRP), the autosomal recessive 
(ARRP) and the X-linked inherited (XLRP) forms. To date, however, 
there are 21, 34 and 2 genes for these forms of RP, respectively,[1] and 
over 230 genes for all forms of RDD worldwide. 
Generally, inherited RDDs are a challenging group of disorders to 
characterise, as they display vast clinical and genetic heterogeneity. 
Nevertheless, providing a genetic diagnosis to patients affords several 
benefits, including predictive, carrier and diagnostic testing for 
family members and participation in current and future gene-based 
clinical trials. 
Genetics in SA has its own unique challenges; the populations, 
both local and immigrant, exhibit genetic diversity of a higher 
order than other population groups.[2] Some groups have remained 
genetically isolated from each other, while others exhibit significant 
admixture. These phenomena have collectively contributed to unique, 
local variations in gene frequencies, noted in all SA population 
groups, which has further confounded genetic diagnosis for RDDs. 
Nevertheless, ‘gene-hunting’ for this group of disorders in SA has 
changed dramatically over the 25 years since the project began, 
largely through evolving molecular technologies, together with the 
computational era and increasing bioinformatics capabilities. This 
article gives an overview of the research efforts in SA into RDD.
The RDD biorepository and database 
in Human Genetics at the University 
of Cape Town (UCT)
Successful gene-hunting relies on good family and phenotype data, 
and to this end an electronic database containing patient and family 
information was constructed. From the outset, the emphasis was not 
only on the collection of biological specimens (mostly blood) but 
that the accompanying data were of the highest standard in order 
to support meaningful genetic analysis. Sampling and pedigree 
collection were carried out by genetic nursing sisters who arranged 
for patients to visit Groote Schuur Hospital in order to confirm their 
diagnoses and to offer clinical management wherever possible.
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‘I was ushered into the world of research regarding RDDs. 
The task was to liaise between affected families, the 
Retinal Preservation Foundation (currently Retina SA) 
and the then Department of Human Genetics at UCT. 
I collected blood samples from the families affected with 
RDDs and extended the families by building pedigrees, a 
challenge that took us back to our founding fathers. The 
blood clinics were carried out with the help of the Retina 
SA branches, nationally, and the genetic nurses from the 
various regional Department of National Health offices 
around the country. Between these organisations we built a 
very healthy relationship with the families, counselling and 
encouraging affected persons to push through, overcome 
their disability and to reach their dreams!’ – LB.
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In 1985, a questionnaire-based survey was 
conducted with local SA families, in order 
to determine the scope of RDDs in the local 
population and whether they would benefit 
from advances in genetic screening. The 
first report on the findings of this initial 
study contained 63 families comprising 130 
affected individuals.[3] This initial cohort of 
families was the foundation upon which the 
biorepository was built. Five years later, in 
1990, a DNA bank[4] and computer-based 
register were established, and by 1995 the 
RDD team reported a cohort of 75 families, 
440 individuals, which included 153 affected 
patients.[4]
The sample collection and analysis 
was ongoing and in 2002 Rebello et al.[5] 
reported a registry of information on 531 
families of 1 829 individuals (comprising 
802 affected RDD patients). At this stage 
the database included the combined clinical, 
biological sample and research data on the 
entire cohort of samples. Interrogation of 
the database led to a report in 2003 by 
the UCT RDD research group that showed 
skewing of samples with strong under-
representation of the indigenous SA ethnic 
groups.[6] Recruiting efforts then focused 
on addressing the potential selection bias 
affecting the ethnic balance of the data 
and, more importantly, providing diagnoses 
and interventions to the previously disad-
vantaged communities in SA. As of Aug ust 
2015, the registry contained 3 237 indi-
viduals in 1 430 families. 
The biorepository remains, however, 
an incomplete portrait of RDD in SA, as 
indigenous Africans comprise only 20% 
of samples, while this demographic group 
actually represents 79%[7] of the total 
population in the country. Additionally, 
information is available for 1 314 individuals 
in SA who have been diagnosed with RDDs 
but from whom biological material has not 
yet been collected. There is therefore an 
ongoing drive to recruit indigenous SA 
families and expand the biorepository.
The biorepository is an invaluable 
resource facilitating the aims of RDD 
research endeavours in SA.
Evolution of molecular 
genetic technologies 
The application of human molecular 
genetics as a tool to identify disease-causing 
mutations underpinning classic Mendelian 
inherited conditions of families have evolved 
over the decades. The traditional research 
methods of the 1970s through to the early 
1990s primarily employed the hypothesis-
driven ‘candidate gene’ linkage approach 
in an attempt to identify RDD genetic loci 
in large pedigrees. However, recent years 
have seen a dramatic shift in both the 
application of molecular genetics and the 
research methodologies used. This shift has 
come about through continued reviewing 
and updating of the research approach, 
underpinned by evolving molecular tech-
nologies. This dynamic approach has supp-
orted a significant increase in the rate of the 
emergence of translational research outputs. 
Fig. 1 gives an outline of RDD research 
milestones against the evolving approaches 
and technologies employed over the past 
25 years. Fig. 2 outlines the number of 
families in whom disease-causing molecular 
defects were identified, using the various 
research approaches and technologies. 
The initial approach used in the gene-
hunting research endeavours of RDD SA 
was linkage analysis using microsatellite 
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Fig. 1. Timeline of milestones reached during the 25 years of retinal research in SA. The black boxes represent international milestones, while the blue 
boxes represent local SA milestones. The molecular approaches used during different time periods are indicated in grey. (CNGS = capture next-generation 
sequencing; WGS = whole genome sequencing; WES = whole exome sequencing.)
Fig. 2. The number of families in the RDD biorepository for whom a genetic diagnosis for RDD was 
determined, using various molecular technologies. 
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markers. These markers had been shown to be tightly linked to genes 
associated with RDD. Candidate gene analyses allowed exclusion of 
linkage from these genes and loci in the five largest SA RDD families. 
This was an important and exciting finding as it presupposed that 
there was possibly a unique molecular aetiology underlying RDD 
in SA.
The emergence of whole chromosome microsatellite marker maps 
enabled researchers to screen the genome for linkage analysis with 
(i) an unbiased and/or (ii) a positional candidate gene approach. The 
latter approach screened for linkage to genes whose products held 
either a structural or biochemical function which facilitate vision, 
but had not previously been implicated in RDD. The application 
of this approach led to the identification of linkage to markers 
on chromosome 17p in the largest RDD family in SA.[8] This 
identification of the RP13 locus was the first major milestone of the 
research endeavours of RDD in SA. Furthermore, not only was it 
the first RDD locus identified in SA, but it was also a novel ADRP 
locus worldwide. Shortly thereafter in 1995, using the same approach 
in another SA RDD family, a second novel ADRP locus, RP17, was 
elucidated, mapping to chromosome 17q.[9]
Subsequent efforts to identify the specific RP13 and RP17 genes 
took 7 and 9 years, respectively. These undertakings involved fine 
mapping and screening of candidate genes in the critical chromosomal 
intervals at the two loci. Candidate genes were selected based 
on reported functions in the visual system. However, ultimately, 
the causative gene at the RP13 locus turned out to be an unlikely 
candidate – a transcription factor, PRPF8,[10] and CA4 (a carbonic 
anhydrase enzyme) was identified as the RP17 gene.[11] This proves 
that the original gene-hunting methods did work, but had significant 
limitations as large families (with many affected and unaffected 
individuals and spanning multiple generations) were required for 
study. 
Advances in the human genome project,[12] the accompanying 
development of denser microsatellite marker maps and the 
characterisation of genes along long chromosomal stretches, facilitated 
more direct approaches to disease-gene hunting. This direct candidate 
gene screening approach involved the targeted analysis of coding 
regions and intron/exon boundaries of candidate genes that had 
been reported internationally for specific mutations. Cohorts of 
patients were selected for each RDD candidate gene screen, based 
on their phenotype (i.e. clinical diagnosis and mode of inheritance) 
and screened for mutations using single stranded conformational 
polymorphism analysis (SSCP), and later the higher throughput 
denaturing high performance liquid chromatography (dHPLC). 
This involved analysing genes, portion by portion (less than 
500bp at a time), in a single affected individual per family, to 
detect mutations. Although large families were not required for this 
candidate screening approach, analysis remained laborious and slow 
and was complicated by the fact that (i) unexpected causative genes 
that were not obvious candidates, e.g. ubiquitously-expressed splice 
factors and transcription factors had previously been associated with 
RDDs; (ii) there is vast clinical and genetic heterogeneity as well as 
significant genetic overlap between different RDDs. These scenarios 
make hypothesis-driven candidate gene selection problematic. 
Nevertheless, the ongoing research in the division has identified the 
causative mutation in several families over the years.[13]
The development of microarray technologies enabled escalation 
of screening to a level that allowed for whole genes to be analysed in 
large cohorts in a relatively short time period. In 2006, microarray 
technology (as offered by Asper Ophthalmics[14] in Estonia) was 
incorporated into the RDD project. Each of 18 ophthalmic ‘DNA 
chips’ allow for the simultaneous screening for all reported mutations 
associated with a particular RDD. For example, the ADRP chip 
currently tests for 414 variants in 16 genes, and the ARRP chip 
currently tests for 710 variants in 28 genes. Using this approach, 
causative mutations are rapidly detected and founder mutations 
recognised and used to create targeted diagnostic tests for the specific 
population groups in which they were identified. An example is the 
test for seven mutations in ABCA4 that are common in individuals of 
Afrikaner ancestry with Stargardt disease,[15] and the test for a single 
mutation in MYO7A that is a frequent cause of Usher syndrome in 
indigenous Africans.[16]
A possible limitation of using the Asper Ophthalmic Microarrays 
is that the array platforms are designed to test for mutations 
reported globally, primarily based on data available from European 
and American individuals, and may not be relevant in the diverse 
population groups of SA. Furthermore, the arrayed primer extension 
(APEX) technology[17] only sequences those select nucleotide 
positions in genes where mutations have been reported previously, 
therefore these chips are unable to detect novel mutations that are 
likely to exist in the unique SA population groups. 
The growing need for an unbiased approach to gene-hunting, 
prompted the use of CNGS, for the first time on the RDD project in 
2012. CNGS, as offered by the National Health Service in Manchester, 
UK[18] enriches all the exons of a panel of target genes for sequencing. 
Initially the CNGS panel comprised the complete coding sequences 
of 105 RDD genes, but currently it allows for the detection of novel 
and/or known variants by sequencing 176 RDD genes. Due to current 
cost considerations, a limited number of samples have been tested 
with this approach (n=11). However, it has proven successful and a 
molecular diagnosis was confirmed in seven families. 
Taken together, the research approaches and technologies employed 
over the years have allowed the identification of the molecular cause 
of RDD disease in 249 families, for whom diagnostic testing is now 
available. The subsequent translational research efforts have seen 
results delivered to 416 individuals based on the work carried out 
in their families. Rewardingly (as of August 2015), 197 families are 
in a position to benefit from emerging gene therapy trials for the 
following genes: RPE65, AIPL1, MYO7A, ABCA4, and CHM.
The future direction for RDD research and gene hunting is to 
employ a true candidate-free approach: using NGS strategies such 
as WGS or WES. The strength of these approaches is that causative 
mutations can be identified without a pre-existing hypothesis of 
which genes to interrogate. This will allow for the detection of not 
only novel mutations in known genes, but novel genes are also likely 
to emerge,[19] resulting in a more comprehensive list of disease-causing 
mutations and the generation of potential key disease modulators. 
Compared with the original techniques, where one gene could take 
months or years to screen, capabilities in 2015 allow for sequencing of 
the entire exome (i.e. all coding portions of all 20 000 - 30 000 known 
human genes) in a matter of days, although the analysis is challenging 
and can take longer, particularly if the clinical information or family 
history is unclear.
Phenotyping and the longitudinal 
study of families 
It is perhaps surprising that given the limited resources, manpower 
and ‘archaic’ labour-intensive technologies that were applied, we 
were able to molecularly diagnose 249 families with several retinal 
phenotypes. The successes can possibly be ascribed to the meticulous 
clinical profiling by the clinical geneticist, genetic nurses and allied 
professionals who laid the foundation for potential discoveries. 
It can therefore be inferred that going forward, the limiting 
factor for new discoveries is perhaps not the invention of new 
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methodologies/technological platforms but rather the integrity of 
the clinical and biological material that is being researched. The 
documentation of the clinical affection status of family members 
is critical; one incorrect diagnosis, e.g. mislabelling of an affected 
individual as unaffected, would compromise the integrity of all 
downstream analyses. This is perhaps the single most important 
lesson to be remembered and applied as we traverse the landscape of 
the modern genomics era. 
While every effort was made at keeping abreast with emerging 
technologies and research approaches, using First-World capabilities 
in a developing country such as SA, the over-arching goal was, and 
remains, the opportunity to offer any findings back to the patients 
and their interested families.[20] With this in mind, the value of 
engaging fully with our research participants,[21] eliciting extended 
family trees with a history of disease through the family and, where 
possible, attempting to trace the origin of the disease back to the 
countries from which the patients might have emerged, is an ongoing 
endeavour in the SA RDD research environment. The longitudinal 
progression of disease in SA RDD families was tracked over the last 
25 years through working with a highly effective national network 
of ophthalmologists. This emphasis on patterns of heritability and 
ophthalmological course of disease is hugely important in terms 
of streamlining the potential gene candidates out of the very many 
involved in RDDs, thereby making research more effective. 
An important aspect to consider is the complex genetic landscape 
of RDDs, which represents a significant challenge for identifying 
therapeutic targets and demonstrating proof-of-concept/s. This 
requires careful consideration of the genetic nature of the disease 
against the mutation prevalence, relative to disease severity and, 
importantly, the age of onset. Interrogation of family data is therefore 
an ongoing exercise.
The real value to families
What is embodied in the research of the RDD programme is a 
commitment to holistic care for individuals with inherited disorders. 
The identification of the causative mutation for an inherited RDD has 
immediate benefits for affected individuals, their families and their 
clinical management team. Establishing a genetic cause confirms the 
clinical diagnosis at a molecular level, enables accurate recurrence 
risk estimation, informed reproductive decision making as well as 
carrier testing or predictive testing (depending on the inheritance 
pattern and age of onset). Furthermore, knowledge of the specific 
gene involved may aid in prognosis, suggest potential therapeutic 
options and allows some patients to join clinical trials. The goal of 
medical research is therefore to aid in the genetic management of 
families, to alleviate disease symptoms through the development of 
treatment modalities, or to find a cure. In keeping with this ideology, 
the initial aim of the research project has been to identify the disease-
causing mutations in patients affected by inherited RDD and to 
translate the research findings into clinical practice and management. 
An important aspect of the SA RDD project has therefore always 
been the delivery of research findings to families. This undertaking 
engages a multidisciplinary team that includes medical scientists, 
medical geneticists, genetic counsellors, ophthalmologists, genetic 
nursing sisters, as well as the lay society, Retina South Africa, the 
registered non-profit and public-benefit lay organisation that has 
funded this research. Diagnostic services have been developed to 
provide a comprehensive clinical genetic service for RDD patients 
and their families in SA. The SA journey from ‘DNA to diagnosis’, 
and the subsequent translational research aspect of the project has, 
moreover, through the incorporation of genetic counsellors into the 
programme, highlighted their value in the uptake of findings and 
management of families. 
With the capability of disease-gene and mutation identification, 
comes the capacity to manage further transmission of the disorder 
within the family through preimplantation genetic diagnosis (PGD), 
which is now available in SA. The process firstly involves in vitro 
fertilisation followed by preimplantation testing of the embryos. 
Embryos shown not to carry the known familial cause of RDD are 
then selected for implantation. Depending on the severity and age 
of onset within the family, some couples might consider prenatal 
diagnostic testing. The ethical and psychosocial issues pertaining 
to prenatal and preimplantation genetic diagnosis are complex 
and should be considered carefully through the process of genetic 
counselling. In 2015, a family with an X-linked form of RDD elected 
to utilise the PGD option that resulted in the birth of a healthy child 
who did not carry the disease-causing X-linked mutation segregating 
in the family. This case illustrates the essential role of clinical genetic 
services related to RDDs throughout SA over the past 25 years. The 
process started with a Cape Town couple from a SA RDD family, DNA 
has been archived from various family members from throughout SA 
and stored at UCT since 1999. The exact molecular genetic mutation 
was identified in 2007 in a laboratory in the UK, and in 2015, it was 
possible for the multidisciplinary team of professionals to facilitate 
PGD for this family with a positive and successful outcome.
Discussion
Notwithstanding the unique challenges in the SA context, RDD 
research efforts over the past 25 years have enjoyed several 
major successes. The identification of novel genes, mutations and 
founder mutations in the SA RDD patient cohort has impacted 
the community, which this research serves, in an indelible manner. 
Furthermore, the research group has been very successful in its 
participation in the global RDD research arena. Group members’ 
contribution to publications and their presentations at local and 
international scientific conferences are ongoing. Much of the 
success can be attributed to the insight and forethought of Prof. 
Peter Beighton and his response by getting involved in a variety 
of areas – he is probably one of the last ‘polymaths’ one will ever 
encounter. In his era, empiric risk calculation was based on more 
than just what the patient presented to the clinician, but also an 
understanding of how the disease affected other members of the 
family. Even then, there was the anticipation of one day finding the 
underlying gene – despite not having the technologies available. 
Over the years, gene hunting approaches have shifted as 
technologies improved and became cost-effective. Every effort has 
been made to introduce new technologies into the research/training/
education environment. This is not only to ensure that trainees 
and postgraduates are exposed to state-of-the-art technologies, and 
trained in the applicability of such technologies, but also to ensure 
that research for the various disorders is performed by highly 
trained researchers in SA, for SA. Advances in molecular genetics 
(and genomics) have infiltrated almost all areas of biology and 
are currently employed as the research tools commonly used in a 
‘The ophthalmological fraternity was always 
accommodating and filed many examination forms for 
us. Included in these reports was accurate documentation 
of the state of the retina and vision of the patient. To 
obtain these, several uncomfortable tests had to be 
undertaken, but it gave us a very accurate status of the 
disease for each individual.’ – LB.
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multidisciplinary environment to explore the molecular mechanisms 
for both common multifactorial diseases and rare Mendelian diseases. 
High-throughput technologies are mostly incorporating hypothesis-
free approaches. Large multi-centre collaborations, exploring genetic 
and environmental contributions to disease, are common practice 
to try and unravel the missing heritability. However, the question 
remains: ‘Have the traditional principles and practices of medical 
genetics  as it relates to detailed clinical phenotyping and recording 
of medical and family history  of the 1970s - 1990s been adopted in 
this new era of the genomics revolution?’ 
What is obvious is that despite the high-throughput technologies 
currently implemented in the laboratory at UCT, the practice of 
true geneticists, as embodied in Peter Beighton, will remain a 
gold standard. This involves the long-term engagement of families 
(and communities) where the research is seen as a jointly driven 
enterprise, committed to feeding back progress in research, as well as 
translating discoveries to patients, families and communities. 
We salute Prof. Beighton for his remarkable wisdom, insight 
and tenacity, and for reminding us that at the heart of research, 
there is a patient and a family. This should be remembered as the 
next generation of scientists are trained in the ‘next-generation’ 
technologies. 
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